Overview

Planning Treatment for Oesophago-gastric Cancer: a Maintenance Therapy Trial

Status:
Recruiting
Trial end date:
2025-06-01
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy of maintenance therapies following completion of standard first-line chemotherapy in patients with locally advanced or metastatic HER-2 positive or HER-2 negative oesophago-gastric adenocarcinomas.
Phase:
Phase 2
Details
Lead Sponsor:
Royal Marsden NHS Foundation Trust
Collaborators:
Clovis Oncology, Inc.
Eli Lilly and Company
MedImmune LLC
Treatments:
Capecitabine
Durvalumab
Ramucirumab
Rucaparib
Trastuzumab